SCHEMBL4058023

SCHEMBL4058023

COc1ccc2cc(NC(=O)O)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
KDM4E B2RXH2 1/20 0.56
PLAU P00749 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TSHR P16473 2/20 0.53
TP53 P04637 1/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
POLB P06746 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
PTGS1 P23219 3/20 0.51
AKR1C3 P42330 3/20 0.51
AKR1C2 P52895 3/20 0.51
PTGS2 P35354 3/20 0.50
RXFP1 Q9HBX9 1/20 0.50
CDC42 P60953 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4064359 0.97 NPC1 (0.57) NPC1RAB9AKDM4EPLAUMEN1
SCHEMBL8027073 0.86 MTNR1A (0.63) NPC1RAB9AKDM4EPLAUMEN1
SCHEMBL992202 0.83 RAB9A (0.73) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL11782014 0.81 POLB (0.55) NPC1RAB9APLAUMEN1KMT2A
SCHEMBL9428464 0.81 MTNR1A (0.65) NPC1RAB9AKDM4EKMT2APOLB
Methane SCHEMBL2365682 0.81 RAB9A (0.70) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL2095227 0.80 RAB9A (0.71) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL31728556 0.80 RAB9A (0.71) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL6313654 0.80 ALDH1A1 (0.59) NPC1RAB9AKDM4EKMT2APOLB
SCHEMBL5022626 0.79 POLB (0.58) NPC1RAB9AKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090182001-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2009-07-16 US disclosed
EP-1910365-A4 INHIBITORS OF CHECKPOINT KINASES MERCK & CO INC (US) 2009-07-15 EP disclosed
EP-1910365-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-16 EP disclosed
WO-2007015837-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182001-A1 Inhibitors of checkpoint kinases CHEK1, CHEK2, BUB1B NPC1 3878/4885RAB9A 2746/4885KDM4E 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.